Exelixis Inc Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Exelixis Inc (EXEL) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $422.42 million for the 9-month period ending 2019-09-27, per its 10-Q filed 2019-10-30.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2019-10-30
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-09-27 was $163.63M, a 79.31% increase year-over-year.
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-06-28 was $128.97M, a 145.92% increase year-over-year.
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2019-03-29 was $129.82M, a 48.36% increase year-over-year.
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2018-12-28 was $49.62M, a 29.37% decline year-over-year.
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2018 was $280.83M, a 16.57% decline from fiscal 2017.
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2017 was $336.59M, a 122.19% increase from fiscal 2016.
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $151.49M.
- Exelixis Inc proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2016 was $151.49M, a 15.34% decline from fiscal 2016.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2019-09-27 | $163.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $292.60M derived: sum of 2 quarters · filed 2019-10-30 | $422.42M 10-Q · filed 2019-10-30 | $472.04M derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-06-28 | $128.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $258.79M 10-Q · filed 2019-07-31 | $308.41M derived: sum of 3 quarters · filed 2019-07-31 | $399.67M derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-03-29 | $129.82M 10-Q · filed 2019-05-01 | $179.44M derived: sum of 2 quarters · filed 2019-05-01 | $270.70M derived: sum of 3 quarters · filed 2019-10-30 | $323.14M derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-12-28 | $49.62M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $140.88M derived: sum of 2 quarters · filed 2019-10-30 | $193.32M derived: sum of 3 quarters · filed 2019-10-30 | $280.83M 10-K · filed 2019-02-22 |
| 2018-09-28 | $91.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $143.70M derived: sum of 2 quarters · filed 2019-10-30 | $231.20M 10-Q · filed 2019-10-30 | $301.46M derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-06-29 | $52.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $139.95M 10-Q · filed 2019-07-31 | $210.20M derived: sum of 3 quarters · filed 2019-07-31 | $275.64M derived: sum of 4 quarters · filed 2019-07-31 |
| 2018-03-30 | $87.50M 10-Q · filed 2019-05-01 | $157.76M derived: sum of 2 quarters · filed 2019-05-01 | $223.20M derived: sum of 3 quarters · filed 2019-05-01 | |
| 2017-12-29 | $70.25M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $135.70M derived: sum of 2 quarters · filed 2019-02-22 | $336.59M 10-K · filed 2019-02-22 | |
| 2017-09-30 | $65.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $266.33M 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $65.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $143.83M derived: sum of 2 quarters · filed 2018-11-01 | $266.33M 10-Q · filed 2018-11-01 | $317.19M derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $78.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $200.89M 10-Q · filed 2017-08-02 | $251.74M derived: sum of 3 quarters · filed 2018-05-02 | $294.04M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | $122.51M 10-Q · filed 2017-05-01 | $173.36M derived: sum of 2 quarters · filed 2018-05-02 | $215.65M derived: sum of 3 quarters · filed 2018-05-02 | $243.88M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $50.85M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $93.14M derived: sum of 2 quarters · filed 2017-11-01 | $121.38M derived: sum of 3 quarters · filed 2017-11-01 | $151.49M 10-K · filed 2017-02-27 |
| 2016-12-30 | $151.49M 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $42.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $70.53M derived: sum of 2 quarters · filed 2017-11-01 | $100.64M 10-Q · filed 2017-11-01 | $149.23M derived: sum of 4 quarters · filed 2017-11-01 |
| 2016-06-30 | $28.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $58.34M 10-Q · filed 2017-08-02 | $106.94M derived: sum of 3 quarters · filed 2017-08-02 | $142.84M derived: sum of 4 quarters · filed 2017-08-02 |
| 2016-03-31 | $30.11M 10-Q · filed 2017-05-01 | $78.70M derived: sum of 2 quarters · filed 2017-05-01 | $114.61M derived: sum of 3 quarters · filed 2017-05-01 | $154.63M derived: sum of 4 quarters · filed 2017-05-01 |
| 2016-01-01 | $178.94M 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $48.59M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $84.50M derived: sum of 2 quarters · filed 2017-02-27 | $124.53M derived: sum of 3 quarters · filed 2017-02-27 | $178.94M 10-K · filed 2017-02-27 |
| 2015-09-30 | $35.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $75.93M derived: sum of 2 quarters · filed 2016-11-03 | $130.34M 10-Q · filed 2016-11-03 | $170.73M derived: sum of 4 quarters · filed 2017-02-27 |
| 2015-06-30 | $40.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $94.44M 10-Q · filed 2016-08-03 | $134.82M derived: sum of 3 quarters · filed 2017-02-27 | |
| 2015-03-31 | $54.41M 10-Q · filed 2016-05-04 | $94.80M derived: sum of 2 quarters · filed 2017-02-27 | ||
| 2014-12-31 | $40.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $252.89M 10-K · filed 2017-02-27 | ||
| 2014-09-30 | $212.51M 10-Q · filed 2015-11-10 | |||
| 2013-12-31 | $325.17M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |